triazoles has been researched along with glpg0634 in 99 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 32 (32.32) | 24.3611 |
| 2020's | 67 (67.68) | 2.80 |
| Authors | Studies |
|---|---|
| Brys, R; Christophe, T; Clement-Lacroix, P; Conrath, K; De Vos, S; Feyen, JH; Fletcher, S; Galien, R; Lepescheux, L; Menet, C; Nelles, L; Smets, B; van 't Klooster, G; van der Aar, EM; Van Rompaey, L; Vandeghinste, N; Vayssiere, B | 1 |
| Blanc, J; Brys, R; Christophe, T; Ciesielski, F; Clement-Lacroix, P; Deprez, P; Fletcher, SR; Galien, R; Geney, R; Jouannigot, N; Lepescheux, L; Menet, CJ; Nelles, L; Smits, K; Uhring, M; van der Aar, EM; Van Lommen, G; Van Rompaey, L; Vayssiere, B | 1 |
| Cox, E; Diderichsen, PM; Namour, F; Tasset, C; Van der Aa, A; Van't Klooster, G; Vayssière, B | 1 |
| Desrivot, J; Harrison, P; Namour, F; Tasset, C; Van der Aa, A; van't Klooster, G | 1 |
| Iwata, S; Kubo, S; Nakayamada, S; Tanaka, Y | 1 |
| Ananthakrishnan, AN | 1 |
| Baranovsky, A; Goldis, A; Harrison, P; Hebuterne, X; Klopocka, M; Kuehbacher, T; Petryka, R; Roblin, X; Schreiber, S; Sike, R; Stoyanova, K; Tasset, C; Van der Aa, A; Vermeire, S; Wisniewska-Jarosinska, M | 1 |
| Cseuz, R; Greenwald, M; Harrison, P; Kavanaugh, A; Kremer, J; Ponce, L; Reshetko, OV; Stanislavchuk, M; Tasset, C; Van der Aa, A; Vanhoutte, F | 1 |
| Alten, R; Enríquez-Sosa, F; Greenwald, M; Harrison, P; Mazur, M; Pavlova, D; Tasset, C; Taylor, PC; Van der Aa, A; Vanhoutte, F; Westhovens, R | 1 |
| Galien, R; Mazur, M; Meuleners, L; Namour, F; Stanislavchuk, M; van 't Klooster, G; Van der Aa, A; Vanhoutte, F; Voloshyn, O | 1 |
| Abdul Azeez, M; Kiriakidis, S; Taylor, PC | 1 |
| Boland, BS; Vermeire, S | 1 |
| Labetoulle, R; Paul, S; Roblin, X | 1 |
| Chen, N; Cui, L; Jing, Q; Ren, F; Ren, G; Si, Y; Sun, H | 1 |
| Genovese, M; Harrison, P; Kavanaugh, A; Meuleners, L; Tasset, C; Van der Aa, A; Westhovens, R | 1 |
| Baek, S; Cho, ML; Choi, SS; Hong, SM; Jang, SG; Kwok, SK; Lee, J; Min, JW; Park, SH | 1 |
| Fagard, L; Harrison, P; Namour, F; Tasset, C; Van der Aa, A; Xin, Y | 1 |
| Mountifield, R | 1 |
| McInnes, IB; Siebert, S | 1 |
| Abi-Saab, W; Besuyen, R; Coates, LC; Dudek, A; Gladman, DD; Greer, JM; Harrison, P; Helliwell, PS; Kunder, R; Mease, P; Meuleners, L; Mozaffarian, N; Rychlewska-Hanczewska, A; Stanislavchuk, M; Tasset, C; Van den Bosch, F; Van der Aa, A | 1 |
| Abi-Saab, W; Baraliakos, X; Besuyen, R; Deodhar, A; Gensler, LS; Greer, JM; Hendrikx, T; Landewé, R; Liu, K; Maksymowych, WP; Meuleners, L; Mozaffarian, N; Nadashkevich, O; Tasset, C; Tseluyko, V; van der Heijde, D | 1 |
| Collison, J | 1 |
| Gadina, M; O'Shea, JJ | 1 |
| Anderson, K; Cuvin, J; Kotecha, M; Namour, F; Qin, AR; Scott, B; Sharma, S; Xin, Y; Zheng, H | 1 |
| Westhovens, R | 2 |
| Battat, R; Dulai, PS; Feagan, BG; Jairath, V; Ma, C; Parker, CE; Sandborn, WJ | 1 |
| Singh, JA | 1 |
| Bartok, B; de Vlam, K; Gao, J; Genovese, MC; Gottenberg, JE; Guo, Y; Kalunian, K; Matzkies, F; Mozaffarian, N; Sundy, JS; Takeuchi, T; Tasset, C; Walker, D | 1 |
| Chi, P; Hong, Z; Shi, H; Sun, Y | 1 |
| Senior, M | 1 |
| Besuyen, R; Coates, LC; Gao, J; Gossec, L; Hendrikx, T; Leung, YY; Meuleners, L; Ogdie, A; Orbai, AM; Tasset, C; Tillett, W; Trivedi, M | 1 |
| Rogler, G | 1 |
| Lee, YH; Song, GG | 4 |
| Anderson, K; Kearney, BP; Kwan, E; Mathias, A; Namour, F; Qin, A; Xin, Y; Yun, C; Zheng, H | 1 |
| Dowty, ME; Hegen, M; Jesson, MI; Katkade, V; Lin, TH; Martin, DA; Menon, S; Telliez, JB | 1 |
| Bonovas, S; Danese, S; Lasa, JS; Olivera, PA; Peyrin-Biroulet, L | 1 |
| Dixit, A; Gabani, BB; Kiran, V; Mohd, Z; Mullangi, R; Trivedi, RK | 1 |
| Lefevre, PLC; Vande Casteele, N | 1 |
| Georgiou, S; Plachouri, KM | 1 |
| Abd Eldaim, MA; Abdallah, AEM; Abdel-Daim, MM; Abdelaziz, SAM; Abdul Rashid, S; Abdullah, AS; Abdullah, LC; Abramson, MJ; Ahmed, HB; Ahmed, MM; Ahn, YC; Alexander, DC; Ando, T; Angelone, AM; Anglani, F; Ap, Y; Arthanari, SK; Axelrad, C; Bai, S; Bakonyi, P; Barnes, E; Beckmann, NA; Bélafi-Bakó, K; Bennett, CM; Bestha, RM; Bitsch, RG; Bradley, CA; Bu, Y; Calò, LA; Cañedo-Villaroya, E; Carlson, L; Caruso, S; Casado-Flores, J; Ceol, M; Cesarino, I; Chen, IL; Chen, R; Chen, X; Chilvers, MI; Cho, WK; Choong, TSY; Conceição-Neto, N; Culver, EL; Dai, X; de Lama Caro-Patón, G; De Rosa, I; Del Prete, D; Dharmage, SC; Dimitriadis, E; Dittakavi, S; Dobrowolski, JC; Edin, S; Elgarawany, GE; Emam, HE; Emmens, RW; Erbas, B; Erwich, JJHM; Farghali, M; Feng, L; Funston, RN; Gabler, NK; Gale, P; Ganesh, M; Gao, J; Gao, L; Gao, X; García-Salido, A; Gatto, R; Gautam, S; Ge, C; Ghogomu, SM; Gianesello, L; Gonçales, VR; Gooch, JL; Gooding, JJ; Gourley, GG; Gu, H; Gu, X; Gu, Z; Guerreri, M; Guillén, M; Hazzaa, SM; Heylen, E; Hicks, R; Hong, X; Hoshi, M; Hu, B; Hu, LX; Hu, R; Hu, S; Huang, J; Huang, K; Hubbard, WB; Hui, J; Hwang, NY; Iannacci, J; Ianus, A; Iglesias-Bouzas, MI; Ihara, I; Iwasaki, M; Jaeger, S; Kandel, YR; Karpińska, G; Kim, HK; Klopfenstein, TJ; Knorr, D; Koók, L; Kotb, S; Kruithof, S; Larsson, P; Laurence, C; Leng, J; Li, H; Li, J; Li, Q; Li, S; Li, X; Li, Z; Lian, J; Liang, JX; Liang, X; Lighaam, LC; Lin, CW; Lin, HC; Lin, J; Ling, A; Liu, J; Liu, P; Liu, YS; Ljuslinder, I; Lo, GH; Lodge, CJ; Löfgren-Burström, A; Lowe, AJ; Lu, M; Lu, N; Lucero-Prisno, DE; Luebbe, KM; Luo, X; Ma, Z; Maes, P; Makuch, M; Malekbala, MR; Mao, Z; Martínez-Romera, I; Marzo, G; Mathew, FM; Mattei, A; Matthijnssens, J; Mayumi, M; Morita, N; Mueller, DS; Mullangi, R; Mummolo, S; Murthi, P; Myte, R; Nabeshima, T; Nakamoto, K; Nehdi, IA; Nemestóthy, N; Niessen, HWM; Noh, JM; Nota, A; Nunes, D; Oh, D; Öhlund, D; Olsen, KM; Ono, H; Osawa, Y; Palmqvist, R; Palombo, M; Park, M; Patience, JF; Peng, Y; Perng, DS; Persano, A; Priante, G; Prince, SJ; Pulipati, S; Pyo, H; Qiu, X; Quan, J; Quaranta, F; Quinzi, V; Rademacher, CJ; Rajaraman, G; Rashid, U; Rauch, JC; Rector, A; Remmerswaal, EBM; Ren, R; Rispens, T; Rocha, GS; Saad, NM; Saito, K; Salamova, A; Sarfaraz, K; Satoshi, A; Schnellmann, RG; Scholpa, NE; Schonhoff, M; Schwartz, KJ; Schwarze, M; Schweer, WP; Seiichi, Y; Serrano-González, A; Severino, J; Shemesh, N; Shi, ZQ; Shike, DW; Shim, YM; Siciliano, PA; Siebenrock, KA; Silva, MKL; Smith, DL; Soltani, S; Song, YM; Spry, ML; Stalker, LA; Stokes, RS; Sullivan, PG; Sun, JM; Sun, S; Svanes, C; Syo, K; Tai, CM; Takashima, S; Tashita, C; Taurino, A; Ten Berge, IJM; Tenuta, AU; Teo, SH; Tilley, RD; Trivedi, RK; Umetsu, K; Unger, PA; van Bruggen, R; van Ham, SM; Van Ranst, M; Vanitha, J; Vekaria, HJ; Venier, M; Venkateshwaran, K; Venkert, A; Vermeulen, E; Wan, C; Wang, H; Wang, N; Wang, P; Wang, T; Wang, X; Wang, Y; Wise, KA; Wolbink, GJ; Wu, J; Wu, P; Wu, S; Wu, Y; Xia, Q; Xin, W; Xiong, Q; Xu, H; Xu, P; Xue, S; Yamamoto, Y; Yamashiro, T; Yan, F; Yan, H; Yan, S; Yan, Y; Yang, JM; Yang, L; Yang, P; Ye, W; Yeh, JH; Yinda, CK; Ying, GG; Ying, L; Yoon, HG; Yu, H; Zainuddin, M; Zakkula, A; Zeller, M; Zeng, Y; Zha, J; Zhang, F; Zhang, H; Zhang, M; Zhang, Q; Zhang, S; Zhang, T; Zhang, Z; Zhao, C; Zhao, J; Zhao, Y; Zhong, Q; Zhu, J; Zingmark, C; Zo, JI; Zou, Y | 1 |
| Gyu Song, G; Ho Lee, Y | 1 |
| Argollo, M; Dal Buono, A; Danese, S; Roda, G | 1 |
| Allocca, M; Correale, C; Danese, S; Fiorino, G; Furfaro, F; Gabbiadini, R; Gilardi, D; Peyrin-Biroulet, L; Zilli, A | 1 |
| Calvi, RM; Chiarella, J; Deeks, SG; Ho, YC; Hoh, R; Jenike, KM; Yeh, YJ | 1 |
| Singh, S | 1 |
| Dixit, A; Gabani, BB; Kiran, V; Mullangi, R; Srinivas, NR | 1 |
| Lee, YH; Sung, YK | 1 |
| Ampaw, L; Anderson, K; Begley, R; Kearney, BP; Mathias, A; Qin, A; Watkins, TR; Weng, W | 1 |
| Aletaha, D; Baraliakos, X; Boehncke, WH; de Wit, M; Dörner, T; Dougados, M; Emery, P; Fleischmann, RM; Geissler, K; Isaacs, JD; Kerschbaumer, A; Kremer, J; Lee, EB; Maksymowych, WP; McInnes, I; Nash, P; Pope, JE; Smolen, JS; Stoffer-Marx, M; Takeuchi, T; Tam, LS; Tanaka, Y; Trauner, M; van den Bosch, F; van der Heijde, D; Voshaar, M; Westhovens, R; Winthrop, KL; Xavier, R | 1 |
| Adas, M; Bechman, K; Cope, AP; Galloway, JB; Mootoo, A; Norton, S; Patel, V; Qureshi, S; Rampes, S; Yates, M | 1 |
| Dhillon, S; Keam, SJ | 1 |
| Amano, K; Atsumi, T; Bartok, B; de Vlam, K; Gao, J; Genovese, MC; Gottenberg, JE; Guo, Y; Ishiguro, N; Kalunian, K; Kondo, A; Matsubara, T; Pechonkina, A; Sugiyama, E; Sundy, JS; Takeuchi, T; Tanaka, Y; Tasset, C; Walker, D; Yamaoka, K | 1 |
| Baker, M; Bubb, M; Chaichian, Y; Chatham, W; Derebail, V; Genovese, M; Gurtovaya, O; Hajian, H; Lim, S; Patel, U; Rao, P; Tumlin, J | 1 |
| Atsumi, T; Bartok, B; Burmester, GR; Ching, DWT; Chopra, A; Guo, Y; Jahreis, A; Kay, J; Landewé, RB; Matzkies, F; Messina, OD; Mozaffarian, N; Rigby, WFC; Stohl, W; Sundy, JS; Tasset, C; van der Heijde, D; Westhovens, R; Yin, Z | 1 |
| Bae, SC; Baraf, HSB; Bartok, B; Combe, B; Genovese, MC; Guo, Y; Jahreis, A; Keystone, EC; Kivitz, A; Kumar, U; Landewé, RBM; Matzkies, F; Mozaffarian, N; Nash, P; Simon, JA; Sundy, JS; Tanaka, Y; Tasset, C; van der Heijde, D; Ye, L | 1 |
| Alten, R; An, D; Besuyen, R; Genovese, MC; Greenwald, M; Kavanaugh, A; Lee, SJ; Meuleners, L; Spindler, AJ; Stanislavchuk, M; Sundy, JS; Tan, Y; Westhovens, RR; Winthrop, KL; Ye, L | 1 |
| Kavanaugh, A; McInnes, IB; Tanaka, Y; Wicklund, J | 1 |
| Campigotto, F; Di Paolo, JA; Galien, R; Meng, A; Murray, B; Traves, PG | 1 |
| Biggioggero, M; Caporali, R; Coletto, LA; Favalli, EG; Raimondo, MG; Ramming, A | 1 |
| Balbaba, M; Çalık, İ; Erdağ, M; Eröksüz, Y; İlhan, N; Ulaş, F; Yıldırım, H | 1 |
| Coates, LC; White, JPE | 1 |
| Lizarraga, A; Mysler, E | 1 |
| Cummings, JRF; Harris, C | 1 |
| Avci, AB; Burmester, GR; Feist, E | 1 |
| Adas, M; Bechman, K; Clarke, B; Galloway, J; Yates, M | 1 |
| Nash, P | 1 |
| Beales, ILP; Besuyen, R; Danese, S; Feagan, BG; Filip, R; Fogel, R; Hibi, T; Hospodarskyy, I; Hsueh, CH; Kempiński, R; Kim, HJ; Liu, X; Loftus, EV; McNally, J; Mehta, R; Nijhawan, S; Peyrin-Biroulet, L; Ritter, T; Rogler, G; Sandborn, WJ; Schreiber, S; Seibold, F; Seidler, U; Tasset, C; Vermeire, S; Watanabe, M; Yun, C; Zhao, S | 1 |
| Fearon, U; Flynn, K; Hanlon, MM; Marzaioli, V; O'Brien, A; Veale, DJ; Wade, SC | 1 |
| Keam, SJ; Kim, ES | 1 |
| Baraliakos, X; Barchuk, W; Besuyen, R; Gilles, L; Hendrikx, T; Landewé, R; Liu, K; Maksymowych, WP; Tasset, C; Østergaard, M | 1 |
| Adami, G; Aletaha, D; Bartok, B; Bird, P; Buch, MH; Burmester, GR; Gaujoux-Viala, C; Guo, Y; Hendrikx, T; Matsumoto, A; Messina, OD; Westhovens, R; Yin, Z | 1 |
| Richez, C; Truchetet, ME | 1 |
| Ahmadu, C; Armstrong, N; Brandts, L; Fayter, D; Grimm, SE; Joore, MA; Kirwan, JR; Kleijnen, J; Misso, K; Riemsma, R; Wijnen, B | 1 |
| Alani, M; Anderson, K; Gong, Q; Nelson, CH; Othman, AA; Tarnowski, T | 1 |
| Downie, B; Fleischmann, R; Gurtovaya, O; Matzkies, F; Mozaffarian, A; Pechonkina, A; Robern, M; Tiamiyu, I; Touma, Z; Wallace, D; Werth, VP | 1 |
| Anderson, K; Hsueh, CH; Othman, AA; Qin, A; Shen, G; Yun, C | 1 |
| Ariani, A; Becciolini, A; Di Donato, E; Lucchini, G; Mozzani, F; Riva, M; Santilli, D | 1 |
| Baraliakos, X; Barchuk, W; Besuyen, R; Gilles, L; Hendrikx, T; Landewé, R; Liu, K; Maksymowych, WP; Østergaard, M | 1 |
| Baraliakos, X; Braun, J; Kiltz, U | 1 |
| Bartok, B; Besuyen, R; Burmester, GR; Chen, K; Genovese, MC; Gottenberg, JE; Jahreis, A; Jiang, D; Kivitz, A; Matzkies, F; Takeuchi, T; Tanaka, Y; Winthrop, KL | 1 |
| D'Haens, G; Galien, R; Grant, E; Liu, J; Roblin, X; Serone, A; Woo, J; Yoon, OK; Zhuo, L | 1 |
| Kim, JW; Kim, SY | 1 |
| Connelly, K; Morand, EF | 1 |
| D'Amico, F; Danese, S; Magro, F; Peyrin-Biroulet, L | 1 |
| Amano, K; Atsumi, T; Bae, SC; Bartok, B; Combe, BG; Guo, Y; Ishiguro, N; Keystone, EC; Kivitz, AJ; Kondo, A; Matsubara, T; Matzkies, F; Nash, P; Pechonkina, A; Sugiyama, E; Sundy, JS; Takeuchi, T; Tanaka, Y; Tasset, C; Yamaoka, K; Ye, L | 1 |
| Amano, K; Atsumi, T; Bartok, B; Burmester, GR; Ching, DWT; Guo, Y; Ishiguro, N; Kondo, A; Matsubara, T; Messina, OD; Pechonkina, A; Sugiyama, E; Sundy, JS; Takeuchi, T; Tanaka, Y; Tasset, C; Westhovens, R; Yamaoka, K; Yin, Z | 1 |
| Bingham, CO; Combe, B; Hu, H; Khalid, JM; Lee, SJ; Nash, P; Walker, D; Ye, L | 1 |
| Anderson, K; Bartok, B; Bellanti, F; Chang, P; Chuang, SM; Comisar, C; Kearney, BP; Mathias, A; Meng, A; Nelson, C; Ni, L | 1 |
| Cao, Y; Jing, T; Li, N; Liu, J; Meng, H; Qiu, Z; Sun, J; Sun, Q; Zhuang, Y | 1 |
| Arterburn, SJ; de Vries, DE; Dekkers, G; Dolhain, RJEM; Gillen, A; Gilles, L; Hellstrom, WJG; Oortwijn, A; Reinisch, W; Ritter, TE; Sikka, SC; Tonussi, C; Van Beneden, K; Vanderschueren, D; Watkins, TR | 1 |
| Anderson, K; Namour, F; Nelson, C; Tasset, C | 1 |
| Feagan, BG; Hibi, T; Le Brun, FO; Loftus, EV; Moerch, U; Oortwijn, A; Sandborn, WJ; Vermeire, S | 1 |
| de Haas, A; Dotan, I; Feagan, BG; Hibi, T; Hsieh, J; Oortwijn, A; Peyrin-Biroulet, L; Rudolph, C; Santermans, E; Taliadouros, V | 1 |
| Colombel, JF; D'Haens, GR; Lee, S; Rimola, J; Serone, A; Taylor, SA | 1 |
| Danese, S; de Haas, A; Faes, M; Hsieh, J; Loftus, EV; Maaser, C; Moerch, U; Oortwijn, A; Rogler, G; Rudolph, C; Schreiber, S; Van Hoek, P; Vermeire, S; Watanabe, M; Zhou, Y | 1 |
38 review(s) available for triazoles and glpg0634
| Article | Year |
|---|---|
Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinases; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Triazoles | 2016 |
Filgotinib for the treatment of rheumatoid arthritis.
Topics: Administration, Oral; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Design; Humans; Janus Kinase 1; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyridines; Triazoles | 2017 |
Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease.
Topics: B-Lymphocytes; Colitis, Ulcerative; Crohn Disease; Humans; Indans; Janus Kinase 1; Janus Kinase Inhibitors; Oligonucleotides; Oxadiazoles; Piperidines; Pyridines; Pyrimidines; Pyrroles; Receptors, Lysosphingolipid; Smad7 Protein; T-Lymphocytes; Triazoles | 2017 |
Filgotinib for the treatment of Crohn's disease.
Topics: Crohn Disease; Disease Progression; Gastrointestinal Agents; Humans; Janus Kinase Inhibitors; Pyridines; Severity of Illness Index; Triazoles; Tumor Necrosis Factor-alpha | 2018 |
Clinical efficacy of new JAK inhibitors under development. Just more of the same?
Topics: Adamantane; Arthritis, Rheumatoid; Azetidines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase 1; Janus Kinase 3; Janus Kinase Inhibitors; Niacinamide; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles; Valine | 2019 |
Innovations in Oral Therapies for Inflammatory Bowel Disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Discovery; Heterocyclic Compounds, 3-Ring; Humans; Indans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Mesalamine; Oxadiazoles; Phosphodiesterase Inhibitors; Piperidines; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Lysosphingolipid; Triazoles | 2019 |
Efficacy of JAK inhibitors in Crohn's Disease.
Topics: Crohn Disease; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Piperidines; Pyridines; Pyrimidines; Treatment Failure; Treatment Outcome; Triazoles | 2020 |
Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Drug Therapy, Combination; Humans; Methotrexate; Network Meta-Analysis; Piperidines; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles | 2020 |
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Topics: Arthritis, Rheumatoid; Azetidines; Herpes Zoster; Heterocyclic Compounds, 3-Ring; Humans; Incidence; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Janus Kinases; Piperidines; Placebos; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Spondylitis, Ankylosing; Sulfonamides; Survival Analysis; Treatment Outcome; Triazoles | 2020 |
Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
Topics: Heterocyclic Compounds, 3-Ring; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Piperidines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Triazoles | 2020 |
JAK inhibitors in chronic plaque psoriasis: What is known so far.
Topics: Adamantane; Azetidines; Humans; Janus Kinase Inhibitors; Janus Kinases; Niacinamide; Nitriles; Piperidines; Prospective Studies; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Triazoles | 2020 |
Topics: Acetaminophen; Administration, Oral; Adolescent; Adsorption; Adult; Allyl Compounds; Amylopectin; Amylose; Anaerobiosis; Animals; Anti-Bacterial Agents; Anura; Arginase; Arthritis, Rheumatoid; Asthma; Atmosphere; B-Lymphocytes; Basic Helix-Loop-Helix Transcription Factors; Bioelectric Energy Sources; Biofilms; Biofuels; Biomarkers; Biopolymers; Bioreactors; Brain; Brain Injuries, Traumatic; Breast Neoplasms; Calibration; Carbon Tetrachloride; Caspase 3; Catalysis; Catechin; Cations; Cattle; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Body; Cell Line, Tumor; Cell Plasticity; Chemical and Drug Induced Liver Injury; Chemistry Techniques, Synthetic; China; Chitosan; Chloride Channels; Chromatography, High Pressure Liquid; Chromosome Mapping; Cognition; Cognitive Dysfunction; Cohort Studies; Colitis, Ulcerative; Colloids; Coloring Agents; Congresses as Topic; Correlation of Data; Crystallization; Cyanoacrylates; Cyclohexane Monoterpenes; Cyprinidae; Cytochrome P-450 CYP1A1; Death, Sudden; Dent Disease; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Disease Progression; Disease Resistance; Disulfides; Drug Monitoring; Drug Stability; Ecotoxicology; Electricity; Electrodes; Endocytosis; Environmental Exposure; Environmental Monitoring; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; Esophageal and Gastric Varices; Esters; Fagopyrum; Female; Ferrosoferric Oxide; Flame Retardants; Flavobacteriaceae; Flow Cytometry; Follow-Up Studies; Formoterol Fumarate; Fusarium; Garlic; Gastrointestinal Hemorrhage; Gene Expression; Genes, Plant; Genetic Markers; Glial Fibrillary Acidic Protein; Gliosis; Global Health; Glutathione Transferase; Glycine max; Gum Arabic; Hemostasis, Endoscopic; Hepatocytes; Hippocampus; Humans; Hydrogen-Ion Concentration; Illinois; Immunoglobulin G; Indoleamine-Pyrrole 2,3,-Dioxygenase; Infant, Newborn; Infant, Small for Gestational Age; Injections, Intraperitoneal; Interleukin-4; Iowa; Iron; Ki-67 Antigen; Kidney; Kinetics; Kynurenine; Lakes; Levofloxacin; Lipid Peroxidation; Lipids; Liver; Liver Cirrhosis, Experimental; Magnetic Fields; Magnetic Iron Oxide Nanoparticles; Male; Manure; Maze Learning; Memory, Short-Term; Metal Nanoparticles; Metals, Heavy; Methane; Mice; Mice, Inbred C57BL; Mice, Knockout; Michigan; Microalgae; Microbial Consortia; Mitochondria; Models, Animal; Models, Chemical; Models, Neurological; Molecular Structure; Molecular Weight; Mutation; Myeloid-Derived Suppressor Cells; NADPH Oxidase 2; Neoplasm Recurrence, Local; Neurites; Neurons; Neuroprotective Agents; NF-kappa B; NIH 3T3 Cells; Nitric Oxide Synthase Type II; Nitrogen; Ohio; Ointments; Ontario; Organelle Biogenesis; Organophosphates; Organophosphorus Compounds; Oxidative Stress; Palladium; Particle Size; Pectins; Phenotype; Phytotherapy; Piperidines; Placenta; Plant Diseases; Plant Extracts; Polymers; Polymorphism, Genetic; Polyphenols; Powders; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Protein Kinase Inhibitors; Protein Structure, Secondary; Proteins; Pyridines; Pyrimidines; Rats, Wistar; Real-Time Polymerase Chain Reaction; Receptors, Aryl Hydrocarbon; Receptors, Chemokine; Receptors, Formyl Peptide; Receptors, Lipoxin; Recovery of Function; Recurrence; Reference Standards; Reference Values; Reproducibility of Results; Respiratory Function Tests; Retrospective Studies; Risk; Sensitivity and Specificity; Sewage; Signal Transduction; Sodium Glutamate; Soil; Solanum tuberosum; Solubility; Solutions; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spermatozoa; STAT3 Transcription Factor; Sulfamethoxazole; Tea; Temperature; Thermodynamics; Thrombin; Treatment Outcome; Triazoles; United States; Viscosity; Waste Disposal, Fluid; Wastewater; Water; Water Pollutants, Chemical; Water Purification; White Matter; Wisconsin; X-Ray Diffraction; Zea mays | 2013 |
Comparative efficacy and safety of 100 mg and 200 mg filgotinib administered to patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials
.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Drug Therapy, Combination; Humans; Janus Kinase 1; Methotrexate; Network Meta-Analysis; Pyridines; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles | 2020 |
Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Biological Products; Heterocyclic Compounds, 3-Ring; Humans; Methotrexate; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles | 2021 |
Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Heterocyclic Compounds, 3-Ring; Humans; Niacinamide; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides; Triazoles | 2020 |
JAK selectivity: more precision less troubles.
Topics: Colitis, Ulcerative; Crohn Disease; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Janus Kinase Inhibitors; Naphthyridines; Nitriles; Piperidines; Pyridines; Pyrimidines; Signal Transduction; Triazoles; TYK2 Kinase | 2020 |
PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD.
Topics: Acetates; Animals; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Heterocyclic Compounds, 3-Ring; Humans; Indans; Indoles; Janus Kinase Inhibitors; Oxadiazoles; Piperidines; Pyridines; Pyrimidines; Quinolones; Sphingosine-1-Phosphate Receptors; Triazoles | 2020 |
JAK-STAT inhibitors: Immersing therapeutic approach for management of rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Clinical Trials as Topic; Cytokines; Humans; Inflammation; Janus Kinase Inhibitors; Janus Kinases; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridines; Signal Transduction; STAT Transcription Factors; Sulfonamides; Triazoles | 2020 |
Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; Humans; Methotrexate; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Sulfonamides; Treatment Outcome; Triazoles | 2021 |
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
Topics: Adamantane; Advisory Committees; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Azetidines; Cytokines; Drug Therapy, Combination; Europe; Heterocyclic Compounds, 3-Ring; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Niacinamide; Piperidines; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Rheumatology; Spondylarthropathies; Spondylitis, Ankylosing; Sulfonamides; Triazoles | 2021 |
Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.
Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Azetidines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Heterocyclic Compounds, 3-Ring; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Piperidines; Psoriasis; Pulmonary Embolism; Purines; Pyrazoles; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic; Risk; Spondylarthropathies; Spondylitis, Ankylosing; Sulfonamides; Triazoles; Venous Thromboembolism; Venous Thrombosis | 2021 |
Filgotinib: First Approval.
Topics: Antirheumatic Agents; Autoimmune Diseases; Humans; Inflammation; Japan; Protein Kinase Inhibitors; Pyridines; Triazoles | 2020 |
Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Pyridines; Triazoles | 2022 |
Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Triazoles | 2021 |
JAK1 selective inhibitors for the treatment of spondyloarthropathies.
Topics: Arthritis, Psoriatic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Pyridines; Spondylarthropathies; Spondylitis, Ankylosing; Triazoles | 2021 |
Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Pyridines; Treatment Outcome; Triazoles | 2021 |
JAK1 inhibition and inflammatory bowel disease.
Topics: Heterocyclic Compounds, 3-Ring; Humans; Inflammatory Bowel Diseases; Janus Kinase 1; Janus Kinase Inhibitors; Piperidines; Pyridines; Pyrimidines; Triazoles | 2021 |
Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis.
Topics: Acetonitriles; Arthritis, Rheumatoid; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Triazoles | 2021 |
The safety of JAK-1 inhibitors.
Topics: Arthritis, Rheumatoid; Chemical and Drug Induced Liver Injury; Diverticular Diseases; Herpes Simplex; Herpes Zoster; Heterocyclic Compounds, 3-Ring; Humans; Immunocompromised Host; Infections; Intestinal Perforation; Janus Kinase 1; Janus Kinase Inhibitors; Latent Infection; Opportunistic Infections; Pyridines; Triazoles | 2021 |
Clinical use of Jak 1 inhibitors for rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Methotrexate; Practice Patterns, Physicians'; Pyridines; Triazoles | 2021 |
Filgotinib in Rheumatoid Arthritis: A Profile of Its Use.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Pyridines; Triazoles | 2021 |
Evaluating filgotinib for the treatment of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Pyridines; Triazoles | 2021 |
Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Arthritis, Rheumatoid; Cost-Benefit Analysis; Humans; Pyridines; Quality-Adjusted Life Years; Technology; Technology Assessment, Biomedical; Triazoles | 2021 |
Significance of structural changes in the sacroiliac joints of patients with axial spondyloarthritis detected by MRI related to patients symptoms and functioning.
Topics: Antirheumatic Agents; Axial Spondyloarthritis; Biological Products; Etanercept; Humans; Janus Kinase Inhibitors; Magnetic Resonance Imaging; Osteogenesis; Physical Functional Performance; Pyridines; Radiography; Sacroiliac Joint; Spine; Symptom Assessment; Triazoles | 2022 |
The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment.
Topics: Adamantane; Colitis; Colitis, Ulcerative; Crohn Disease; Heterocyclic Compounds, 3-Ring; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Janus Kinases; Niacinamide; Piperidines; Pyridines; Pyrimidines; Pyrroles; Triazoles | 2021 |
Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis.
Topics: Algorithms; Biological Products; Colitis, Ulcerative; Humans; Janus Kinase Inhibitors; Male; Pyridines; Triazoles | 2022 |
Filgotinib: A Clinical Pharmacology Review.
Topics: Arthritis, Rheumatoid; Humans; Janus Kinase Inhibitors; Pharmacology, Clinical; Pyridines; Triazoles | 2022 |
Filgotinib in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinase Inhibitors; Pyridines; Triazoles | 2023 |
30 trial(s) available for triazoles and glpg0634
| Article | Year |
|---|---|
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Healthy Volunteers; Humans; Janus Kinase 1; Male; Middle Aged; Phosphorylation; Pyridines; Triazoles | 2015 |
Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions.
Topics: Adult; Animals; Antirheumatic Agents; Biotransformation; CHO Cells; Cricetulus; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Glucuronosyltransferase; Humans; Janus Kinase 1; Male; Membrane Transport Proteins; Methotrexate; Microsomes, Liver; Midazolam; Middle Aged; Protein Kinase Inhibitors; Pyridines; Recombinant Proteins; Risk Assessment; Substrate Specificity; Transfection; Triazoles | 2016 |
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Analysis of Variance; Crohn Disease; Double-Blind Method; Drug Administration Schedule; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Pyridines; Treatment Outcome; Triazoles; Young Adult | 2017 |
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
Topics: Administration, Oral; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemoglobins; Humans; Infections; Janus Kinase 1; Male; Methotrexate; Middle Aged; Protein Kinase Inhibitors; Pyridines; Retreatment; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome; Triazoles | 2017 |
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
Topics: Administration, Oral; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Hemoglobins; Humans; Infections; Janus Kinase 1; Male; Methotrexate; Middle Aged; Protein Kinase Inhibitors; Pyridines; Severity of Illness Index; Surveys and Questionnaires; Triazoles | 2017 |
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Janus Kinase 1; Male; Methotrexate; Middle Aged; Pyridines; Treatment Outcome; Triazoles; Young Adult | 2017 |
Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Janus Kinase 1; Male; Methotrexate; Middle Aged; Patient Reported Outcome Measures; Protein Kinase Inhibitors; Pyridines; Treatment Outcome; Triazoles | 2018 |
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
Topics: Accidental Falls; Antirheumatic Agents; Arthritis, Psoriatic; Double-Blind Method; Drug Therapy, Combination; Female; Headache; Hip Fractures; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Male; Middle Aged; Nasopharyngitis; Opportunistic Infections; Pneumonia; Pyridines; Severity of Illness Index; Triazoles | 2018 |
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
Topics: Adult; Antirheumatic Agents; Double-Blind Method; Female; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Male; Middle Aged; Nasopharyngitis; Opportunistic Infections; Pneumonia; Pyridines; Severity of Illness Index; Spondylitis, Ankylosing; Treatment Outcome; Triazoles | 2018 |
The Relative Bioavailability and Effects of Food and Acid-Reducing Agents on Filgotinib Tablets in Healthy Subjects.
Topics: Administration, Oral; Adult; Biological Availability; Famotidine; Female; Food-Drug Interactions; Healthy Volunteers; Humans; Janus Kinase 1; Male; Middle Aged; Omeprazole; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyridines; Tablets; Triazoles; Young Adult | 2019 |
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein; Dose-Response Relationship, Drug; Double-Blind Method; Drug Tolerance; Female; Hematologic Tests; Humans; Infections; Janus Kinase 1; Male; Middle Aged; Pyridines; Remission Induction; Severity of Illness Index; Triazoles | 2019 |
Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR).
Topics: Adaptation, Psychological; Arthritis, Psoriatic; Double-Blind Method; Fatigue; Humans; Janus Kinase Inhibitors; Least-Squares Analysis; Minimal Clinically Important Difference; Pain; Physical Functional Performance; Psoriasis; Pyridines; Quality of Life; Sleep Wake Disorders; Social Behavior; Treatment Outcome; Triazoles | 2020 |
Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Healthy Volunteers; Heart Rate; Humans; Janus Kinase 1; Long QT Syndrome; Male; Middle Aged; Protein Kinase Inhibitors; Pyridines; Triazoles | 2020 |
Topics: Acetaminophen; Administration, Oral; Adolescent; Adsorption; Adult; Allyl Compounds; Amylopectin; Amylose; Anaerobiosis; Animals; Anti-Bacterial Agents; Anura; Arginase; Arthritis, Rheumatoid; Asthma; Atmosphere; B-Lymphocytes; Basic Helix-Loop-Helix Transcription Factors; Bioelectric Energy Sources; Biofilms; Biofuels; Biomarkers; Biopolymers; Bioreactors; Brain; Brain Injuries, Traumatic; Breast Neoplasms; Calibration; Carbon Tetrachloride; Caspase 3; Catalysis; Catechin; Cations; Cattle; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Body; Cell Line, Tumor; Cell Plasticity; Chemical and Drug Induced Liver Injury; Chemistry Techniques, Synthetic; China; Chitosan; Chloride Channels; Chromatography, High Pressure Liquid; Chromosome Mapping; Cognition; Cognitive Dysfunction; Cohort Studies; Colitis, Ulcerative; Colloids; Coloring Agents; Congresses as Topic; Correlation of Data; Crystallization; Cyanoacrylates; Cyclohexane Monoterpenes; Cyprinidae; Cytochrome P-450 CYP1A1; Death, Sudden; Dent Disease; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Disease Progression; Disease Resistance; Disulfides; Drug Monitoring; Drug Stability; Ecotoxicology; Electricity; Electrodes; Endocytosis; Environmental Exposure; Environmental Monitoring; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; Esophageal and Gastric Varices; Esters; Fagopyrum; Female; Ferrosoferric Oxide; Flame Retardants; Flavobacteriaceae; Flow Cytometry; Follow-Up Studies; Formoterol Fumarate; Fusarium; Garlic; Gastrointestinal Hemorrhage; Gene Expression; Genes, Plant; Genetic Markers; Glial Fibrillary Acidic Protein; Gliosis; Global Health; Glutathione Transferase; Glycine max; Gum Arabic; Hemostasis, Endoscopic; Hepatocytes; Hippocampus; Humans; Hydrogen-Ion Concentration; Illinois; Immunoglobulin G; Indoleamine-Pyrrole 2,3,-Dioxygenase; Infant, Newborn; Infant, Small for Gestational Age; Injections, Intraperitoneal; Interleukin-4; Iowa; Iron; Ki-67 Antigen; Kidney; Kinetics; Kynurenine; Lakes; Levofloxacin; Lipid Peroxidation; Lipids; Liver; Liver Cirrhosis, Experimental; Magnetic Fields; Magnetic Iron Oxide Nanoparticles; Male; Manure; Maze Learning; Memory, Short-Term; Metal Nanoparticles; Metals, Heavy; Methane; Mice; Mice, Inbred C57BL; Mice, Knockout; Michigan; Microalgae; Microbial Consortia; Mitochondria; Models, Animal; Models, Chemical; Models, Neurological; Molecular Structure; Molecular Weight; Mutation; Myeloid-Derived Suppressor Cells; NADPH Oxidase 2; Neoplasm Recurrence, Local; Neurites; Neurons; Neuroprotective Agents; NF-kappa B; NIH 3T3 Cells; Nitric Oxide Synthase Type II; Nitrogen; Ohio; Ointments; Ontario; Organelle Biogenesis; Organophosphates; Organophosphorus Compounds; Oxidative Stress; Palladium; Particle Size; Pectins; Phenotype; Phytotherapy; Piperidines; Placenta; Plant Diseases; Plant Extracts; Polymers; Polymorphism, Genetic; Polyphenols; Powders; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Protein Kinase Inhibitors; Protein Structure, Secondary; Proteins; Pyridines; Pyrimidines; Rats, Wistar; Real-Time Polymerase Chain Reaction; Receptors, Aryl Hydrocarbon; Receptors, Chemokine; Receptors, Formyl Peptide; Receptors, Lipoxin; Recovery of Function; Recurrence; Reference Standards; Reference Values; Reproducibility of Results; Respiratory Function Tests; Retrospective Studies; Risk; Sensitivity and Specificity; Sewage; Signal Transduction; Sodium Glutamate; Soil; Solanum tuberosum; Solubility; Solutions; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spermatozoa; STAT3 Transcription Factor; Sulfamethoxazole; Tea; Temperature; Thermodynamics; Thrombin; Treatment Outcome; Triazoles; United States; Viscosity; Waste Disposal, Fluid; Wastewater; Water; Water Pollutants, Chemical; Water Purification; White Matter; Wisconsin; X-Ray Diffraction; Zea mays | 2013 |
Lack of Drug-Drug Interaction Between Filgotinib, a Selective JAK1 Inhibitor, and Oral Hormonal Contraceptives Levonorgestrel/Ethinyl Estradiol in Healthy Volunteers.
Topics: Adult; Contraceptives, Oral, Hormonal; Cross-Over Studies; Drug Combinations; Drug Interactions; Ethinyl Estradiol; Female; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Levonorgestrel; Middle Aged; Pyridines; Triazoles; Young Adult | 2021 |
Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2).
Topics: Adult; Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Finches; Humans; Japan; Methotrexate; Pyridines; Treatment Outcome; Triazoles | 2022 |
Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy.
Topics: Glomerulonephritis, Membranous; Humans; Lupus Erythematosus, Systemic; Pyridines; Triazoles | 2020 |
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Finches; Humans; Methotrexate; Pyridines; Treatment Outcome; Triazoles | 2021 |
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.
Topics: Adalimumab; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Pyridines; Triazoles | 2021 |
Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Methotrexate; Pyridines; Treatment Outcome; Triazoles | 2021 |
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
Topics: Adult; Colitis, Ulcerative; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Janus Kinase Inhibitors; Male; Pyridines; Remission Induction; Treatment Outcome; Triazoles | 2021 |
Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial).
Topics: Adult; Humans; Janus Kinase Inhibitors; Magnetic Resonance Imaging; Metaplasia; Pyridines; Sacroiliac Joint; Spondylarthritis; Spondylitis, Ankylosing; Triazoles | 2022 |
Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Prognosis; Pyridines; Treatment Outcome; Triazoles | 2021 |
Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants.
Topics: Adult; Atorvastatin; Cross-Over Studies; Drug Interactions; Healthy Volunteers; Humans; Pravastatin; Pyridines; Rosuvastatin Calcium; Triazoles | 2022 |
Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study.
Topics: Double-Blind Method; Humans; Janus Kinase Inhibitors; Lupus Erythematosus, Cutaneous; Protein Kinase Inhibitors; Pyridines; Severity of Illness Index; Treatment Outcome; Triazoles | 2022 |
Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Finches; Humans; Japan; Methotrexate; Pyridines; Treatment Outcome; Triazoles | 2022 |
Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3)
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Finches; Humans; Japan; Methotrexate; Pyridines; Treatment Outcome; Triazoles | 2022 |
The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Humans; Methotrexate; Patient Reported Outcome Measures; Pyridines; Quality of Life; Treatment Outcome; Triazoles | 2022 |
Exposure-response relationships for the efficacy and safety of filgotinib and its metabolite GS-829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Janus Kinase Inhibitors; Pyridines; Treatment Outcome; Triazoles | 2022 |
MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases.
Topics: Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Male; Pyridines; Semen; Sperm Motility; Triazoles | 2022 |
32 other study(ies) available for triazoles and glpg0634
| Article | Year |
|---|---|
Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases.
Topics: Animals; Cell Differentiation; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Gene Silencing; Humans; Inflammation; Inhibitory Concentration 50; Interleukin-6; Janus Kinase 1; Male; Mice; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Rats; STAT1 Transcription Factor; T-Lymphocytes, Helper-Inducer; Triazoles | 2013 |
Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.
Topics: Adenosine Triphosphate; Animals; Arthritis; Chemistry, Pharmaceutical; Collagen; Crohn Disease; Crystallography, X-Ray; Cytokines; Dimerization; Disease Models, Animal; Drug Design; Drug Evaluation, Preclinical; Humans; Inhibitory Concentration 50; Janus Kinase 1; Kinetics; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Rats; Recombinant Proteins; Structure-Activity Relationship; Triazoles | 2014 |
Filgotinib for Crohn's disease-expanding treatment options.
Topics: Crohn Disease; Humans; Pyridines; Triazoles | 2017 |
Antisolvent Recrystallization Strategy to Screen Appropriate Carriers to Stabilize Filgotinib Amorphous Solid Dispersions.
Topics: Crystallization; Drug Carriers; Drug Stability; Excipients; Hypromellose Derivatives; Janus Kinase 1; Polymers; Povidone; Protein Kinase Inhibitors; Pyridines; Solubility; Triazoles | 2018 |
JAK-1 Inhibition Suppresses Interferon-Induced BAFF Production in Human Salivary Gland: Potential Therapeutic Strategy for Primary Sjögren's Syndrome.
Topics: Animals; B-Cell Activating Factor; Disease Models, Animal; Epithelial Cells; Humans; Interferons; Janus Kinase 1; Leukocytes, Mononuclear; Mice; Mice, Inbred NOD; Pyridines; RNA, Messenger; Salivary Glands; Signal Transduction; Sjogren's Syndrome; Triazoles | 2018 |
Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Area Under Curve; Female; Glomerular Filtration Rate; Humans; Janus Kinase 1; Kidney Diseases; Male; Metabolic Clearance Rate; Middle Aged; Pyridines; Triazoles | 2018 |
Positioning biologics-A case-based discussion: Surgery and clinical trials.
Topics: Administration, Oral; Adult; Antibodies, Monoclonal, Humanized; Biosimilar Pharmaceuticals; Combined Modality Therapy; Crohn Disease; Digestive System Surgical Procedures; Female; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Infliximab; Male; Pregnancy; Pregnancy, High-Risk; Pyridines; Randomized Controlled Trials as Topic; Recurrence; Severity of Illness Index; Triazoles; Ustekinumab; Young Adult | 2018 |
The extending scope of kinase inhibition in immune diseases.
Topics: Humans; Immune System Diseases; Janus Kinase 1; Protein Kinase Inhibitors; Pyridines; Spondylitis, Ankylosing; Triazoles | 2018 |
Selective JAK inhibition for AS.
Topics: Humans; Janus Kinase 1; Protein Kinase Inhibitors; Pyridines; Spondylitis, Ankylosing; Triazoles | 2018 |
Selective Janus kinase inhibitors come of age.
Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Pyridines; Triazoles | 2019 |
Filgotinib, a JAK1 Inhibitor, for Treatment-Resistant Rheumatoid Arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Finches; Humans; Janus Kinase 1; Pyridines; Triazoles | 2019 |
Inhibition of JAK1 mitigates postoperative ileus in mice.
Topics: Animals; Disease Models, Animal; Gastrointestinal Motility; Humans; Ileus; Inflammation Mediators; Intestinal Mucosa; Janus Kinase 1; Jejunum; Male; Mice; Muscle Contraction; Muscle, Smooth; Peroxidase; Postoperative Complications; Preoperative Care; Pyridines; Signal Transduction; Triazoles; Up-Regulation | 2019 |
Biotech giant helps itself without swallowing Galapagos whole.
Topics: Biotechnology; Drug Industry; Humans; Pyridines; Triazoles | 2019 |
Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Cell Line; Cytokines; Enzyme Assays; Female; Healthy Volunteers; Heterocyclic Compounds, 3-Ring; Humans; Inhibitory Concentration 50; Janus Kinase 1; Janus Kinase Inhibitors; Male; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptors, Cytokine; Sulfonamides; Triazoles | 2019 |
Validated LC-MS/MS method for quantitation of a selective JAK1 inhibitor, filgotinib in rat plasma, and its application to a pharmacokinetic study in rats.
Topics: Animals; Chromatography, Liquid; Drug Stability; Linear Models; Male; Pyridines; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Triazoles | 2020 |
Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; Humans; Methotrexate; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles | 2020 |
Filgotinib suppresses HIV-1-driven gene transcription by inhibiting HIV-1 splicing and T cell activation.
Topics: CD4-Positive T-Lymphocytes; HIV Infections; HIV-1; Humans; Jurkat Cells; Lymphocyte Activation; Pyridines; RNA Splicing; Transcription, Genetic; Triazoles | 2020 |
Novel methodology to perform incurred sample reanalysis on dried blood spot cards: Experimental data using darolutamide and filgotinib.
Topics: Animals; Chromatography, Liquid; Dried Blood Spot Testing; Limit of Detection; Linear Models; Male; Mice; Mice, Inbred BALB C; Pyrazoles; Pyridines; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tandem Mass Spectrometry; Triazoles | 2020 |
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Cells, Cultured; Cytokines; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Janus Kinases; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Sulfonamides; Triazoles | 2021 |
Protective effect of filgotinib in rat endotoxin-induced uveitis model.
Topics: Animals; Endotoxins; Interleukin-6; Pyridines; Rats; Rats, Wistar; Triazoles; Tumor Necrosis Factor-alpha; Uveitis | 2021 |
Targeting JAK-STAT Signalling Alters PsA Synovial Fibroblast Pro-Inflammatory and Metabolic Function.
Topics: Adamantane; Adult; Aged; Arthritis, Psoriatic; Azetidines; Cells, Cultured; Female; Fibroblasts; Heterocyclic Compounds, 3-Ring; Humans; Inflammation; Janus Kinase Inhibitors; Janus Kinases; Male; Middle Aged; Niacinamide; Purines; Pyrazoles; Pyridines; Signal Transduction; STAT Transcription Factors; Sulfonamides; Synovial Membrane; Triazoles | 2021 |
Evaluation of the potential drug interactions mediated through P-gp, OCT2, and MATE1/2K with filgotinib in healthy subjects.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Interactions; Healthy Volunteers; Humans; Pyridines; Triazoles | 2022 |
Filgotinib as rheumatoid arthritis therapy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Pyridines; Triazoles | 2021 |
Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial.
Topics: Humans; Inflammation; Magnetic Resonance Imaging; Pyridines; Severity of Illness Index; Spine; Spondylarthritis; Spondylitis, Ankylosing; Triazoles; Vertebral Body; Zygapophyseal Joint | 2022 |
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinase Inhibitors; Pyridines; Triazoles | 2022 |
Effects of JAK1-Preferential Inhibitor Filgotinib on Circulating Biomarkers and Whole Blood Genes/Pathways of Patients With Moderately to Severely Active Crohn's Disease.
Topics: Biomarkers; C-Reactive Protein; Crohn Disease; Cytokines; Feces; Humans; Interleukin-6; Janus Kinase 1; Janus Kinase Inhibitors; Leukocyte L1 Antigen Complex; Pyridines; Severity of Illness Index; Triazoles | 2022 |
Filgotinib in cutaneous lupus: is a negative positive?
Topics: Double-Blind Method; Humans; Lupus Erythematosus, Cutaneous; Protein Kinase Inhibitors; Pyridines; Triazoles | 2022 |
Contributions of intestine and liver to the absorption and disposition of FZJ-003, a selective JAK1 inhibitor with structure modification of filgotinib.
Topics: Amides; Animals; Caco-2 Cells; Humans; Intestinal Absorption; Intestines; Janus Kinase 1; Janus Kinase Inhibitors; Liver; Microsomes, Liver; Pyridines; Rats; Triazoles | 2022 |
Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study.
Topics: Adrenal Cortex Hormones; Colitis, Ulcerative; Humans; Janus Kinase Inhibitors; Prednisone; Pyridines; Triazoles | 2023 |
Efficacy of Filgotinib in Patients with Ulcerative Colitis by Line of Therapy in the Phase 2b/3 SELECTION Trial.
Topics: Biological Products; Colitis, Ulcerative; Humans; Janus Kinase Inhibitors; Pyridines; Triazoles | 2023 |
Filgotinib for the Treatment of Small Bowel Crohn's Disease: The DIVERGENCE 1 Trial.
Topics: Crohn Disease; Humans; Intestinal Diseases; Pyridines; Triazoles | 2023 |
Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE.
Topics: Adult; Biological Products; Colitis, Ulcerative; Humans; Pyridines; Triazoles | 2023 |